Table 4. Registered trials of the bile acids for neurodegenerations.

Status	Study title	ClinicalTrials.gov Identifier	Condition	Study design	Intervention
Completed	Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment	NCT02841306	Rhegmatogenous Retinal Detachment	Phase 1 clinical trial Non-randomized Parallel Assignment Open labeled	UDCA 26 participants
Recruiting	Trial of Ursodeoxycholic Acid (UDCA) for Parkinson Disease: The “UP” Study	NCT03840005	Parkinson Disease	Phase 2 clinical trial Placebo Controlled, Randomized Double Blind	UDCA 30 participants
Not yet recruiting	Brain Bioenergetics in Parkinson Disease and Response to Repeated Oral UDCA Treatment	NCT02967250	Parkinson Disease	Phase 1 clinical trial Non-randomized Open labeled Single Group Assignment	UDCA 20 participants
Unknown status	Ursodiol in Huntington's Disease	NCT00514774	Huntington Disease	Phase 1 clinical trial Randomized Parallel Assignment Double Blind	UDCA 21 participants
Recruiting	Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis	NCT03800524	Amyotrophic Lateral Sclerosis	Phase 3 clinical trial Placebo Controlled, Randomized Double Blind	TUDCA 440 participants
Recruiting	A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis	NCT03423121	Progressive Multiple Sclerosis	Phase 1–2 clinical trial Placebo Controlled, Randomized Double Blind	TUDCA 60 participants
Recruiting	Study to Assess the Safety and Biologic Activity of AMX0035 for the Treatment of Alzheimer Disease	NCT03533257	Alzheimer Disease	Phase 2 clinical trial Placebo Controlled, Randomized Double Blind	AMX0035 (TUDCA and Phenylbutyrate) 100 participants
Active, non- recruiting	AMX0035 in Patients With Amyotrophic Lateral Sclerosis	NCT03127514	Amyotrophic Lateral Sclerosis	Phase 2 clinical trial Placebo Controlled, Randomized Double Blind	AMX0035 (TUDCA and Phenylbutyrate) 132 participants
Enrolling by invitation	Open Label Extension Study of AMX0035 in Patients With Amyotrophic Lateral Sclerosis	NCT03488524	Amyotrophic Lateral Sclerosis	Phase 2 clinical trial Single Group Assignment Non-randomized Open label	AMX0035 (TUDCA and Phenylbutyrate) 132 participants